These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19224348)

  • 1. Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.
    McGree JM; Eccleston JA; Duffull SB
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):101-23. PubMed ID: 19224348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
    Bazzoli C; Retout S; Mentré F
    Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to handling pharmacodynamic baseline responses.
    Dansirikul C; Silber HE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):269-83. PubMed ID: 18446428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Fisher information matrix approximation methods in population optimal design calculations.
    Strömberg EA; Nyberg J; Hooker AC
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):609-619. PubMed ID: 27804003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model.
    Bach T; An G
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):581-595. PubMed ID: 33884580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the nonparametric estimation method in NONMEM VI.
    Savic RM; Kjellsson MC; Karlsson MO
    Eur J Pharm Sci; 2009 Apr; 37(1):27-35. PubMed ID: 19159684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonlinearity detection: advantages of nonlinear mixed-effects modeling.
    Jonsson EN; Wade JR; Karlsson MO
    AAPS PharmSci; 2000; 2(3):E32. PubMed ID: 11741248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.
    Baverel PG; Savic RM; Wilkins JJ; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):297-315. PubMed ID: 19572188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical evaluation of clinical trial design for a population pharmacokinetic study--a case study.
    Nakade S; Nishibori A; Okamoto H; Higuchi S
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):381-9. PubMed ID: 15548850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.
    Hooker AC; Staatz CE; Karlsson MO
    Pharm Res; 2007 Dec; 24(12):2187-97. PubMed ID: 17612795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fast method for testing covariates in population PK/PD Models.
    Khandelwal A; Harling K; Jonsson EN; Hooker AC; Karlsson MO
    AAPS J; 2011 Sep; 13(3):464-72. PubMed ID: 21725709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of uncertainty parameters estimated by different population PK software and methods.
    Dartois C; Lemenuel-Diot A; Laveille C; Tranchand B; Tod M; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):289-311. PubMed ID: 17216368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous optimal experimental design on dose and sample times.
    Nyberg J; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):125-45. PubMed ID: 19319484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.
    Merlé Y; Tod M
    J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):363-88. PubMed ID: 11677932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood.
    Almquist J; Leander J; Jirstrand M
    J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):191-209. PubMed ID: 25801663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.
    Daimon T; Goto M
    Stat Med; 2007 Jun; 26(14):2799-812. PubMed ID: 17072822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.